Drug intelligence / Profile preview

BI 3034701

Development stage: Phase 2
Lead developer: Boehringer
Modality: Peptides, Small Molecules
Administration: Subcutaneous

Overview

BI 3034701 is a long-acting, next-generation, first-in-class triple agonist peptide developed for the treatment of obesity. It is being advanced by Boehringer Ingelheim in collaboration with Gubra. The drug is currently in Phase I clinical trials and is designed to be administered via subcutaneous injection. While its precise mechanism of action has not been fully disclosed, it is described as a "triple agonist," suggesting activity at three metabolic hormone receptors—potentially similar to other agents targeting GLP-1, GIP, and glucagon receptors—though this has not been explicitly confirmed by the developers. The primary indication under investigation for BI 3034701 is obesity[1][2][3][4][5].

Other names: BI 3034701BI3034701BI-3034701

Targets

GPR1GRM2 (mGluR2)FFAR3 (Free fatty acid receptor 3)

Beyond the preview

Go deeper on BI 3034701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 3034701.

Explore the full profile